Close Ad

The Spoon

Daily news and analysis about the food tech revolution

Cultured Meat

Cultimate Foods Raises €700k To Develop Cultivated Fat for Hybrid Alt-Meat Products

Fat is sexy, don’t you know? In particular, the type of fat made without killing any animals.

One company working on such a fat is Cultimate Foods, a Berlin-based startup developing cultivated fat for hybrid alt-meat products. The company announced it has raised a pre-seed €700 thousand round led by Big Idea Ventures, ProVeg International, and Realum.cloud.

According to a press release sent to The Spoon, Cultimate plans on targeting its cultivated fat at food companies interested in developing hybrid plant-based meat products. The company, which claims its cultivated fat replicates the structure of animal fat tissue, says it uses a “unique technological approach to 3D cultivation creates the structure of their ingredient and reduces the costs of production.”

“Our ultimate goal is to deliver a game-changing ingredient for the plant-based meat industry,” said Cultimate cofounder George Zheleznyi. “We are focused on developing the most important part of meat experience, fat. Cultimate will deliver all the properties of meat that are currently lacking in the available meat alternatives.”

Zheleznyi previously cofounded a Russian-based alt-meat startup called Greenwise. His cofounders at Cultimate include Eugenia Sagué (co-CEO, ex-ProVeg) and Oskar Latyshev (CTO, ex-Partner M).

Cultimate enters an increasingly crowded market for alt-fat products. San Francisco-based Mission Barns raised a significant round last year to help it scale up its cell-cultured fat, and Steakholder Foods (previously MeaTech 3D) is also working on a cultivated fat for its 3D-printed alt-steaks.

Cultimate says it plans to use its new funding to validate its cultivated fat product and begin to prepare for pilot-stage production.

With $5.2M in New Funding, Forsea Forgoes Scaffolding in Attempt to Create Faster Path to Cultivated Meat

Cultivated meat, meet the organoid.

The rapid advance of technology used to create these small, three-dimensional collections of cells grown outside of a living being has created excitement over the past decade-plus in the medical research community, but now a startup named Foresea wants to use organoid technology not to save human lives, but instead that of eels and other seafood. The Israel-based startup, which today announced $5.2 million in seed funding according to a release sent to The Spoon, has developed a technology that utilizes organoids grown in bioreactors to produce eel meat.

According to the company, using organoids allows it to bypass the use of scaffolding, the technology typically used in cultivated meat creation to give meat its structure and texture. Forsea also claims that its technology can grow cultivated meat with fewer bioreactors as well as significantly less growth factors than is typically used in the cultivated meat creation process.

“While cell cultivation largely focuses on a system of directed differentiation, where cells are signaled to differentiate into a specific cell type and are then combined on a scaffold, our system grows the aggregate of the various cells already at the initial stage of the process,” Iftach Nachman, a cofounder of Foresea and inventor of the technology, explained. “The cells organize themselves autonomously into their innate, purposed structure, just as in nature.”

Forsea makes a point in their announcement that their technology creates standalone organisms utilizing an ex vivo methodology. This means that unlike in vitro (which literally translates to “in glass”) approaches where cells are isolated and separated from their natural biological surroundings, Foresea’s organoids are taken from living organisms and grown with minimal alteration from their natural conditions.

Forsea’s is one among a string of announcements over the past year focused on producing proteins at lower cost and with higher efficiency. Whether through new hybrid techniques, lower-cost growth factors, or new approaches to infrastructure, the cultivated meat industry’s focus has shifted beyond proving bench-scale viability to creating scalable solutions for mass-market production. With the introduction of the organoid as a platform for cultivated meat, Forsea has put an intriguing new approach on our watch list for the future of food.

Israel’s Profuse Technology Raises $2.5M for Technology That Lowers Cost of Cultured Meat

As the world awaits the arrival of cultured meat, manufacturers and their suppliers strategize to cope with the realities of this potentially mammoth market. Infrastructure and product scaling for growth remain a challenge from the supply side. Still, concerns over the pricing of lab-grown meat, poultry, and seafood might be the most significant roadblock to consumer acceptance.

Israeli-based Profuse Technology believes it has a solution to bring manufacturing costs down to a point where a pound of cultured beef could achieve price parity with meat from a live animal. A step forward, the company has announced the completion of a $2.5 million seed funding round (and a total of $3.75m since its establishment). The round is led by New York-based investment firm Green Circle and existing shareholders – OurCrowd, Tnuva, and Tempo. Other new investors include Siddhi Capital, a leader in investments in cultivated meat, and Kayma, the investment arm of De-Levie, a meat industry specialist.

According to the announcement, the company will use the funds to collaborate with cultivated meat producers, obtain FDA regulatory approval, and expand the research and development team and its laboratories. The funds will also position the company to source significant capital raising at the end of the second quarter of 2023 to commercialize its customer collaborations.

Profuse’s solution is based on what it calls “a cocktail” that is added during the period when a harvested animal stem cell begins its proliferation process. As founder and CTO Dr. Tamar Eigler-Hirsh told The Spoon: “You would start with a biopsy, and it could be directly from the muscle tissue or an embryonic stem cell harvested from an animal. The cultivated meat companies would take these cells, bank the most successful ones, and optimize them. They would grow them in bioreactors and expand and expand and proliferate these cells until they have hundreds of millions of cells per milliliter. And then, at some point, they have to differentiate the cells to become muscle tissue or muscle fibers. This is where our media supplement comes in.”

“What we’ve basically found a way was to target this natural biological mechanism of regeneration by understanding the biological pathway that that that’s responsible for that,” Dr. Eigler-Hirsh continues. “There’s one protocol to make muscle, and everybody follows it, and it’s very inefficient. Right now, we’re hearing numbers being reported about between 10% to 30% efficiency in converting stem cells into muscle. And using our technology, we can bump that number up from 30% well to over 90% efficiency in conversion of stem cell to muscle.”

Greater efficiency yields more muscle which in turn leads to cultured meat. The math is simple: a more significant and efficient supply can bring down manufacturing costs, which can be passed on to the consumer.

Profuse founder and CEO Guy Nevo Michrowski goes into further detail on the issue of price parity. . First, you won’t need as many cells to start with because your efficiency of using the cells will be 95%. So instead of going for 30 days, you’re going for only 25 days. And most important, the most expensive days are being saved. So, in the last ten days, where over 85% to 90% of the median cost is consumed, those days are cut by half because you don’t need as many cells. And then also, the differentiation and fusion maturation phase of creating them is now reduced to two days instead of ten. Your overall process is only 27 days versus 40 days, which means your factory can produce 33% more yearly.”

Using technology developed at the Weitzman Institute, the company started in 2021. In 2022 it began collaborating with cultivated meat companies and others who potentially would be our distribution partners. Michrowski said that Profuse is working with the major players in the cultured meat and poultry space” And I would say that of the ten leading companies worldwide, we are working with the vast majority together “to demonstrate and quantify the effects of our cocktail on their specific production environment. We operate with different customers to demonstrate our value in different viable development environments and methods.”

Shiru’s Partnership With Puratos Adds Further Credibility to its Protein Discovery Platform

In the world of food tech, decisions made on viable data are good, and a lot of data is even better. But with Shiru, a functional ingredient discovery company, with a dataset of more than 450 million known proteins, you are in rarified air and a welcome partner to forward-thinking companies.

With that in mind, Shiru has announced a new partnership with Puratos, a Belgium-based company that supplies food ingredients for bakeries. Shiru’s Flourish platform will evaluate naturally occurring proteins that could serve as a next-generation egg replacement.

“At Puratos, we truly believe that collaborations can fuel innovation within the food ecosystem,” stated Paul Baisier, Chief R&D Officer at Puratos. “As a company rooted in biology and science, Shiru is the perfect partner in the Puratos’s journey to finding novel uses for proteins discovered by Shiru’s Flourish platform as functional food ingredients that are sustainable, healthy, and delicious. Together with Shiru, we will be able to accelerate our plant-based product innovation pipeline for the benefit of our customers and consumers.”

Julian Lewis, Shiru’s Vice President of Business Development, told The Spoon why his company is excited about this partnership. “(Puratos) will help us scale up these (egg replacement) proteins using their fermentation facilities to a large kind of food grade sample, where we can then do more extensive food application testing. And through this partnership, we have a clear path to fully scaling these ingredients and bringing them to market.”

At this stage of its life cycle, Alameda, Calif.-based Shiru lives for such a partnership. Its database Flourish Flourish uses AI and machine learning to analyze its database of nearly 450 million proteins found in nature. Each application—for example, a plant-based meat company that wants to add taste to its burgers—identifies ingredients that will solve that specific functional ingredient challenge. This business model, Lewis explains, might expand to his company by commercializing some of its discoveries.

“There’ll be other food categories where we might collaborate, or we might do it ourselves,” Lewis said of opportunities down the road. “We might end up in a hybrid where we’re doing some stuff ourselves and collaborating with experts in other fields just to accelerate its market path.”

Functionality is Shiru’s secret sauce, which is the ability to target a specific property of a particular food product. Lewis explains:

“There are three categories we can play in. There’s replace in which we substitute an ingredient for one that, for example, doesn’t work properly. A second is taste. And what we mean by that is some plant-based foods are not that good, and I have yet to find a vegan cheese that works. Lastly, it is to transform. What new foods could be generated in the future that is not replacing traditional products, which are just new things? And maybe we can do that by discovering new functional protein.”

One of the side benefits of working with a complex database is the ability to help food manufacturers get away from using relatively unhealthy ingredients in some plant-based products that give the impression of being a clean alternative. “We’re aiming to provide a much better toolkit of ingredients to the food developers trying to create plant-based foods,” Lewis said.

Lewis adds that while Shiru is currently generally focused on the plant-based world, there’s no reason it will not be a player as the cultured food business develops. “All food has, I would say, taste and texture challenges, so with cultured meats, some additional ingredients may be required. And we’re already working on the early stage with players in that space as well. Our goal is to create more sustainable food ingredients that are both required and interesting.”

Israeli Startup Mermade Gets Seed Funding for Its Lab-Grown Scallops

Mermade is more than just another food tech startup with a laboratory-oriented process to manufacture an alternative protein. The Jerusalem-based company’s method of using algae to create scallops has set it apart and attracted significant early-stage investment.

The company has announced an oversubscribed $3.3M seed round as it showcases a circular cellular agriculture technology for producing cultivated scallops. In doing so, Mermade attacks two problems at once: bringing sustainable, good-tasting scallops to the public at a below current market price. Most cultured meat companies struggle with the economics of meeting or beating the cost of beef, chicken, or conventional seafood.

In an interview with The Spoon, company Co-Founder and CEO Daniel Einhorn explained the differences in his company’s business and technology approach. “We thought is why not pick some meat product that eliminates as much as possible of that food engineering challenge and just focus on those huge biological challenges,” Einhorn said. “Scallops, they have a fairly similar size, and each unit is a fairly similar size and shape. And texture taste is the same all throughout the cuts. Those are huge unfair advantages compared to our direct competition– other startups trying to replicate the more complex meat products.”

Mermade says it is the first company in the world to produce scallops using cellular agriculture. The company intends to develop a product and reach laboratory-scale production by 2023, reaching consumers and restaurants after that. Mermade will use the funds to employ more stem cell and algae researchers, accelerating the company towards this goal. The scallop is the first product the company will develop out of a diverse seafood portfolio that will gradually arrive on the market.

The use of algae to recycle the cells’ growth substrate is a clear distinction for Mermade. This cellular interpretation of traditional aquaponics was termed by the company Cytoponics, and the company has filed several patent applications related to this circular production method.

Related to the cost issue, Einhorn states, “It’s a big market segment and one that it has a very high price point, which is important because the main challenge right now is driving costs down. We’re trying to integrate all parts of our design into this prototype to bring cost even close to market parity.”

“In the next few years, consumers worldwide will be able to buy cultivated scallops (Coquilles Saint Jacques) made by Mermade in a supermarket or restaurant, at an affordable price and with the same quality and taste as the original food. Using Cytoponics as our production platform, we could also produce a variety of other cultivated seafood products such as calamari, shrimp, crab meat, and more.”

The company was founded in July 2021 by Daniel Einhorn (CEO), Dr. Rotem Kadir (CTO), and Dr. Tomer Halevy (COO). Investors in the seed round include the investment platform OurCrowd, Israel’s most active venture firm; Fall Line, an American VC fund specializing in AgTech; and prominent Dutch investor Sake Bosch.

Alternative seafood—both plant-based and cell-cultured—is a hot area. As The Spoon reported in April, Good Food Institue’s report, which looks at the entire alternative seafood category across plant-based, cell-cultured, and fermentation-based products, said 2021 investment brought the total invested in the category to $313 million from 2013 through 2021. Cultivated seafood startups commanded two-thirds of all investment in alt-seafood last year at $115 million, compared with $58 million invested in plant-based seafood startups and $2 million in fermentation-based seafood.

Among the companies active in this space are Wildtype, UPSIDE Foods, Gathered Foods, and Finless Foods. With all the activity in this forward-looking space, the United States—in the form of the USDA and FDA—has yet to give the green light for sales of these lab-grown alternative proteins. Only Singapore, Qatar, and to some degree, The Netherlands have given their stamp of approval.

SuperMeat Believes An Open Source Approach to Cultivated Meat Will Benefit All

Lab-grown or cultured meat is a sexy topic that fulfills the dream of healthy eating while saving the planet’s precious resources. Most of the headlines focus on the companies in the four corners of the world waiting for regulators to wave the checkered flag. The more interesting story—at least for those who enjoy looking under the hood—is in the processes, supply chain, and partnerships vital to this promising industry.

To understand the drill-down of what it takes to go from harvesting animal cells to creating consumer-facing products, it’s valuable to speak with visionaries such as Ido Savir, CEO of Israel’s SuperMeat. In addition to his knowledge of cultivated meat, Savir’s background in IT provides him with a panoramic view of the infrastructure needed to build a successful B2B company.

While it might not qualify as an awe-inspiring announcement, SuperMeat recently received a grant from the Israeli Innovation Authority to establish an open-source high-throughput screening system for optimizing cultivated meat feed ingredients. As an analogy, think of it as a system that ensures cows or chickens receive only the best quality feed to produce larger quantities of high-grade meat or chicken. But there is a significant difference.

Savir explains that animals are inefficient producers of their products. “It’s just done more efficiently (in cultivated meat),” the SuperMeat CEO told The Spoon in a recent interview. “In traditional meat production, 70% to 80% of the cost comes from the feed, and animals are just not very efficient conversion machines.” To put it into perspective, the cost of animal component-free (ACF) feed can make or break those vying to play in this space.

Rather than compete with consumer-facing brands such as Future Meat, Eat Just, and Mosa Meat (to name a few), SuperMeat is taking a B2B approach. Working with established meat and poultry providers to build production facilities where companies with existing supply chains can quickly enter the future of the alt-meat market. SuperMeat has announced deals with Germany’s PHW Group and Migros in Switzerland. The Israeli firm is in discussion with potential U.S. partners to reach the stateside market by the end of 2023.

The decision to build a platform for cultivated meat rather than build its own consumer brand directly results from Savir’s tech background, and it is also why the new feed screening system is in the open-source approach. “From my background, and I really believe in open source, and I really believe in sort of a platform approach that can help bring not just one company but the industry forward,” Savir stated.

Also, speaking to his tech background, it’s clear Savir has learned the relationship between capital expenditures and profit. It’s not about cost; it’s about having the right model.

“The way I look at this, and it doesn’t matter how much the infrastructure costs,” he said. “What matters is how efficient and the return you can get from that money. Right. And if you can get that return in a reasonable time, it makes sense, no matter what the cost is. We have our cost of goods models that demonstrate that that makes sense.”

A trip to SuperMeat’s facility in Israel will yield more than a view of lab equipment and many steel fermentation tanks. The facility includes a small restaurant-like space called “The Chicken,” where potential business partners, consumers, and others can taste the lab-grown animal protein. Savir says it’s more than just a pretty place to show off.

“We’re trying to do things a bit differently,” Savir said. “We thought it was important for us and our potential clients, which are food companies, to have that full transparency and traceability.”

See video of the makeshift eatery below:

World's First Cultivated Meat Blind Tasting Full Reel

Eat Just’s GOOD Meat Lines Up Partners to Scale Up Cultivated Meat Production

The great cultivated meat scale-up has begun. Or, at the very least, the game plan for one of the industry’s most high-visibility players is finally coming into view.

That startup is Eat Just, Inc., which has announced two significant partnerships for its Good Meat group, the company’s cultivated meat division, over the past week. The first partnership, announced last week, is with food/ag conglomerate ADM, which will partner with Eat Just to optimize the growth factors and nutrients in the cell culture growth media. According to the announcement, the two will work together to create a growth medium “for quality, cost and volume.”

The second partnership, announced today, is with ABEC, a biomanufacturing engineering and services company, to build out Good Meat’s manufacturing facilities. The multi-year agreement will see ABEC “design, manufacture, install and commission the largest known bioreactors for avian and mammalian cell culture.”

According to the announcement, the deal is for the production of ten 250,000-liter bioreactors, which will form the foundation for GOOD Meat’s large-scale cultivated meat facility. The production complex, which will be located in the United States, will have the capacity to produce up to 30 million pounds of cultivated meat. The new facility will initially produce chicken and beef products and have a nationwide distribution footprint.

While 30 million pounds sounds like a lot, it represents less than one-tenth of one percent of the aggregate meat consumption in the US. Still, it’s not nothing. The planned production represents a significant leap over any other announced production capacity (Upside’s pilot plant, announced last year, will eventually have a capacity of 400 thousand pounds of meat per year).

Some may dismiss these efforts as hardly making a dent in overall meat consumption but Eat Just’s Josh Tetrick and others have made it clear that the effort to scale up this industry will take decades, not years. These efforts to produce cell-cultivated meat at this scale will undoubtedly provide lessons for an industry collectively looking to figure out the science and technology of doing something that’s never been done before.

 

Meati Adds Steak Filets to Its Roster of Mycelium Alt-Meats

Meati co-founder Tyler Huggins radiates the right blend of entrepreneurial enthusiasm and practical knowledge to catapult common mushroom threads into a popular staple for healthy consumers. Huggins walks the walk as a visionary in the future of food space with a diverse background that includes a stint as a field biologist for the U.S. Forest Service, a research engineer, a consultant in the wastewater industry, and a co-founder of a healthy snack company.

“I really dedicate my life to harnessing nature’s power and beauty and then guiding it to help produce sustainable food,” Huggins told The Spoon in a recent interview.

With initial success from the launch of Meati’s mycelium-based alt-chicken and alt-beef cutlets, the company has announced a new product, Meati Steak Filet, which will be available on May 23 directly to consumers through the company’s website. Four steak filets, which should be prepared much as one would cook a steak, will sell for $35.

Like other Meati offerings, the steak fillets are a whole food rich in nutrition. A single serving has only 0.5g of fat and zero cholesterol. It is 120 calories along with 14g of protein, 9g of dietary fiber, and a host of micronutrients such as Riboflavin, Niacin, Folate, Vitamin B12, Zinc, and Copper.

The fermentation process from mushroom roots to the finished product has evolved to become a smooth, sustainable effort, but years of hard work are behind Meati’s success.

“There was a lot of trial and error. We spent over two years and millions of dollars of government grant money to figure out the cultivation and the fermentation part of this process,” Huggins explained.  
And then it was, how do you take all these mushrooms and actually make meat out of it? That was a whole other couple of years because what we do is we make sure we ensure wholesome nutrition. The mushroom roots are actually alive during the entire process. We gently form and orientate the root structure in different ways to mimic different muscles and give you different textures.”

Huggins said that Meati is in the midst of a significant physical expansion, but in doing so, the company looked at other industries for ways to scale without reinventing the wheel. “We looked into other industries and found several analogs. Our existing processes are already scaling, and we said, okay, we’ll take one from here and another from food processing. And we’ve created this unique sort of hybrid of industrial processes where we don’t need some sort of technological breakthrough to be successful.”

The future for Meati includes testing retail distribution in the second half of 2022 and a continued effort to create a brand sanction between itself and the countless other alt-meat products. Beneath it all, Huggins’ passion for delivering a clean, healthy, nutritious product is his and Meati’s north star.

“I look at nature as sort of a toolbox, you know,” Huggins said. “Three billion years of evolution have designed all sorts of different tools. And I believe that most of our problems can be solved by looking into nature because nature’s problem is already solved.”

Melt&Marble Raises €5 Million For Fermentation-Derived Fat That Tastes and Melts Like the Real Thing

In the first wave of plant-based “meat,” the marketing challenge was about convincing customers that giving up meat needn’t create a hole in their regular diet. For the Impossibles, Beyonds, and others, developing a reasonable, tasty facsimile to the beef or chicken experience got them into millions of homes and in demand on grocer’s shelves. For plant-based meat products to become a savory choice rather than a substitute requires innovators to “kick it up a notch.”

 While the horse race to alt-burger dominance is on, off to the side, innovators have been working on plant-based beef fat that would offer the mouthfeel and umami taste to a host of faux meat products. Included in the alt-beef fat space is Swedish company Melt&Marble which secured a €5 million Series Seed financing round to scale-up production and expand its team.

 Melt&Marble uses precision fermentation to create its plant-based beef fat. Like others in the alternative protein, dairy, meat, and seafood world know, precision fermentation is a robust process but requires a lot of capital to build a proper scalable infrastructure. CEO and Co-Founder Dr. Anastasia Krivoruchko told The Spoon that her company is currently at a lab-scale but will start scaling up in the coming months. It will still be a couple of years until it is fully industrial scale.

Dr. Kriviruchko believes the opportunity for Mouth&Marble is now and in the future based on conversations with plant-based meat providers. “We have talked with many companies about the challenges they are facing with their existing fats,” she said. “When designing our yeast strains, we have been looking into the structure of beef fats and asking ourselves what elements are important for overcoming these challenges. Our prototype has a similar mouthfeel and melting profile to beef fat, which is extremely important for replicating the taste of beef.”

This begs the obvious question about the health-related issues, such as high cholesterol and heart disease, that come with consuming “real” beef fat. Dr. Kriviruchko says such concerns are not present with plant-based beef fat.

“Generally, our fats don’t contain cholesterol, trans-fats, and contaminants. With our technology, we could also potentially integrate healthy bioactive fatty acids into our fats, and this is something that we are keen to explore,” Melt&Marble’s CEO explained.

Melt&Marble’s technology platform was spun out from research work conducted over the past decade by co-founders Dr.  Krivoruchko,  Dr.  Florian  David, and  Professor  Jens  Nielsen at the Chalmers  University of  Technology in  Sweden.  Lever VC led the latest round; an early-stage venture capital firm focused on technologies and brands in the alternative protein space. Lever has previously invested in Good Plant, The Good Spoon, A Dozen Cousins, and others.

If it appears that plant-based beef fat (and other related healthy fats) is a niche market, the number of trailblazers in this emerging sector speaks otherwise. Among Melt&Marble’s competition are Meat-Tech, Mission Barnes, Nourish Ingredients, Hoxton Farms, and Cubiq Foods.

According to Grand View Research, Inc., the global plant-based meat market size will reach $24.8 billion by 2030. A likely scenario, familiar to most emerging tech markets, will be when a few of the best alt-beef fat companies survive by being purchased by either a mega food processor such as Tyson or Cargill or merge with a plant-based market leader like Impossible Foods or Beyond Meat.

IndieBio Startup CellCrine is Developing Serum-Free Growth Media That Reduces Costs by 90%

Growth medium is widely recognized in the cell-cultured meat industry as one of the nascent sector’s biggest cost drivers. According to a survey conducted by the Good Food Institute in 2020, growth media made up 80% or more of the total operating cost for 38% of those cell-cultured meat manufacturers who responded, while 72% of respondents indicated that growth media made up half or more of their total operating costs.

As a result, a number of startups have been working on developing new approaches to create lower-cost growth media. One of these companies is CellCrine, which claims to be developing the world’s cheapest serum-free growth media. As a member of IndieBio’s 12th cohort, CellCrine pitched their idea this week at the biotech accelerator’s Demo Day.

CellCrine’s media utilizes what it says are proteins that are currently not a component of any media sold today. These proteins act as “cell culture activator” that coordinates the cell growth process and brings out the best performance from within cells. According to the company, adding these proteins as a supplement to cultured cell growth media “reduces the need for all other growth factors and recombinant proteins 90% or more.”

“How does it work? It helps cells help themselves,” CellCrine cofounder and CEO Dr. Rodolfo Faudoa says in the pitch video.

Faudoa first started working on growth media when he was working on his postdoc at USC’s Department of gene therapy. There he developed serum-free growth media for Schwann cells from the auditory nerve. He succeeded and was recruited to Stanford University where he worked on scarless wound healing.

According to Faudoa, once a growth culture is initiated using a small concentration of these unique proteins, they no longer need any more. From there, the cells start to secrete their own growth factors by pumping up the autocrine and paracrine signaling among cells.

Last year the company started applying the proteins to meat cells and the results were impressive. According to CellCrine, the cells grow better with their proteins than in 20% fetal bovine serum. The company has established 4 master cell lines – two for chicken and two for pork cells have tailored essential media supplements for each.

The company is currently working on several pilots with different cell cultured meat companies who are testing out their growth supplements. Like most companies coming out of IndieBio, they are looking for additional partners and are, we presume, going to be talking to investors.

You can watch CeleCrine’s demo day pitch video below:

Cellcrine (IndieBio SF Demo Day 12)

Fermentation May Be Centuries Old, But It’s Attracting a Whole Bunch of New Money ($1.69 Billion to Be Exact)

You know what they say: everything old is new brewed again.

At least that’s true when it comes to fermentation, that ancient food and beverage production process that is currently an overnight sensation. It is going well beyond the time-honored probiotic-rich staples of sauerkraut, kefir, pickles, miso, yogurt, and kombucha. The process of fermentation is being utilized in the creation of alternative, sustainable proteins to take the place of meat, eggs, seafood, and dairy. And it’s projected to get even more significant in its scope and revenue.

Data in The Good Food Institute’s 2021 State of Fermentation Industry Report points to the growth of fermentation as a traditional means to create probiotic-rich foods and plant-based products. According to the report, a total of $1.69 billion was invested in 54 fermentation-based startups in 2021.

Other data from GFI’s report:

  • Fifteen known startups dedicated to fermentation for alternative proteins were founded in 2021, along with new suppliers focused on fermentation-enabled alternative protein ingredients.
  • Eighty-eight known companies are now dedicated to fermentation-enabled alternative proteins, increasing 20 percent from the number of known companies in 2020.
  • 2021 saw the first growth-stage fundraising in the fermentation industry, including three deals >$200 million.

It’s important to understand that fermentation is not a single process but is three separate processes. Traditional fermentation (used to make pickles, kombucha, and sauerkraut) uses live organisms (such as the fungus Rhizopus to make tempeh or a SCOBY to brew kombucha) to modulate ingredients to create a product rich in flavor and texture. One established company, Miyoko’s Creamery, uses fermentation to make its line of alternative protein dairy products.

 A second process, biomass fermentation, takes advantage of the properties of certain microorganisms that quickly create large quantities of protein. The resulting protein can be used as a standalone product or an ingredient, which is the focus of most companies in this area. An example of a company employing biomass fermentation is SACCHA, a  German company using spent brewer’s yeast to create an alternative vitamin-rich protein that can be used to develop animal-free metal. Colorado-based Meati Foods uses mycelium (a mushroom root) to create a fibrous material that resembles meat.

 Precision fermentation, the third method, is perhaps the segment in this area with tremendous potential and is a focus of major investments. In precision fermentation, microbes create “cell factories” to build specific functional ingredients. Precision fermentation can produce enzymes, flavoring agents, proteins, vitamins, natural pigments, and fats. EVERY Company is an example of this process in which precision fermentation creates a substitute for traditional egg whites.

The GFI chart below shows the different types of fermentation as they relate to alternative proteins and highlights different possible products enabled by each.

One of the most significant stumbling blocks for the more advanced fermentation methods is the buildout of large-scale facilities to tackle production. A growing number of companies are in the process of recently completing or midst such construction, which points to 2023 as a timeframe in which production could begin to fulfill a growing market.

GFI’s report points to these as examples of completed projects and ones in the process of buildout:

  •               The Protein Brewery, Netherlands, completed 2021
  •               The Better Meat Co., California, completed in 2021
  •               Nature’s Fynd, Chicago, targeted for 2022-2023
  •               Mycorena. Sweden, expected to be completed in 2022
  •               Solar Foods, Finland, to be completed in 2022        

 With all the noise about the more advanced forms of fermentation, the value and growth of products in the “traditional fermentation” space have been overlooked. The kombucha market has skyrocketed with a focus on health, especially during the COVID-19 scare. According to Absolute Reports, the global Kombucha market size is estimated to be worth $2.1 billion in 2022 and is forecast to be $6.1 billion by 2028, with a CAGR of 19.7%.

 And an old fermented standby, sauerkraut, also brings in big dollars. According to Verified Market Research, the sauerkraut market was valued at $8.7 billion in 2019 and is projected to reach $14.1 billion by 2027, growing at a CAGR of 5.74% from 2020 to 2027.

UPSIDE’s New Investment Dollars Pushes The Company To the Front of the Cultivated Meat Line

Picture this: It’s late 2023, or perhaps 2024. Renowned Austin pitmaster and entrepreneur Aaron Franklin finishes up tending to his smokers after a long night of preparing to feed the onslaught of barbeque fans. Those queued up along Branch Street in East Austin are in for a surprise; that day, instead of the usual prime brisket rubbed with Aaron’s secret coffee-based rub, the star of the day is meat that comes from a place other than a ranch and slaughterhouse. Welcome to the world of cultivated meat.

In such a scenario, UPSIDE Foods is likely to be at the forefront of cultivated meat choices for restaurants and later consumers. Armed with an additional $400 Million in Series C financing, the Berkeley, Calif.-based company is among the leaders in the cultivated meat, poultry, and seafood industry. With these new funds, UPSIDE (formerly Memphis Meats), reaches the milestone of a $1 billion valuation. The funds will be used to expand its production footprint, additional R&D for the next generation of products, consumer education, and enhance its supply chain.

Yes, it is a gamble to fund companies in the cultivated meat space given the lack of governmental approval in the form of the FDA and USDA. Amy Chen, UPSIDE’s COO, admits she has no crystal ball, regarding when cultivated meat will get the green light in the U.S., but is confident the market demand will encourage governments-not just in the U.S.—to provide thoughtful oversight without becoming a roadblock.

“We have had years of extensive dialogue and collaboration with the regulators,” Chen told The Spoon in a recent interview. “We are fully confident that globally there is a market for it and there are eager governments that will pursue it.”

The Series C round is co-led by Temasek, a global investment company headquartered in Singapore, and the Abu Dhabi Growth Fund (ADG), a new investor. Other new investors include Baillie Gifford, Givaudan, John Doerr, SALT fund, and Synthesis Capital. They are joined by existing investors Bill Gates, Cargill,  Cercano Management, CPT Capital, Dentsu Ventures, Singapore-based global investor EDBI, Kimbal and Christiana Musk, Norwest Venture Partners, SoftBank Vision Fund 2, SOSV’s Indie Bio, and Tyson Foods.

Chen is especially proud of the large cross-section of investors that represent varied interests from venture firms to companies entrenched in the agricultural space that produce conventional meat and poultry. It is that wide range of support, she believes, that will help in consumer education as well as a long-term presence in the new food chain.

That said, there’s a lot of work that goes into convincing consumers to bite into a new type of food that is, to say the least, unconventional. Chen suggests that there is a group of early adopters in place ready to sample something new that offers a premium taste while providing the start of a solution to creating a more sustainable global food supply.

“When I think about the adoption of any new technology,” UPSIDE’s COO commented, “There are always the cutting-edge early adopters. Folks who have two characteristics – one is they love food and are open to the next thing in food with an openness to innovation and new things. The other trait is being aware and an interested in addressing some of the challenges of conventional meats.”

The bottom line for Chen is the fact that her company’s cultivated meat has the taste of the real thing. “One of the things I am super passionate about, coming from the food world, is the taste of the Product,” she said.  “Ultimately, if it doesn’t taste good when the consumer puts it into their mouth, we have lost the journey.”

UPSIDE is not alone in this quest to bring cultivated meat to the masses. There’s Brazil’s JBS, Israel’s SuperMeat, GOOD Meat, and Mosa Meats, just to name a few. There are also other companies offering technology to aid in the process that facilitates the cultivation process. According to the Good Food Institute, 21 new companies in the cultivated meat space launched in 2021, a 32% increase from the previous year.

 Approval from the FDA comes in the form of a “no questions” letter from the FDA, followed by the USDA’s investment in plant inspection and labeling guidelines. Beyond those hurdles, there are other questions: will cultivated meat be considered Kosher/Halal (given there is no ritual slaughter)? And how will this new product be merchandised in stores? Does it belong in the current meat section alongside 80/20 ground round? Lastly, how will vegans react? No animal is killed, so how will those avoiding all things steak, hamburgers, et al react?

Only time will tell.